Dolutegravir (new scientific evidence (§13): HIV infection, patients aged 5 - < 18 years)

Subject:

• Active Substance: Dolutegravir
• Name: Tivicay^®
• Therapeutic area: HIV infection
• Pharmaceutical company: ViiV Healthcare GmbH

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 15.09.2022

Final decision:

• Previous decisions remain valid